Drug intelligence / Profile preview

NTx-043

Development stage: Preclinical
Lead developer: Nuclide Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

NTx-043 is a discovery-stage radiopharmaceutical being developed by Nuclide Therapeutics for the treatment of therapy-resistant solid tumors. The agent is part of a next-generation radionuclide therapy platform that conjugates a therapeutic radionuclide to a small-molecule targeting moiety. While the specific molecular target and the isotope have not been disclosed, the program is designed to address solid tumors that have become resistant to standard-of-care therapies. The program is currently in the discovery phase, approaching preclinical development.

Beyond the preview

Go deeper on NTx-043.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTx-043.

Explore the full profile